Molecular Cancer Research · 2021 · 41 citations · 61 references
MedicineMolecular GeneticsOncologyCancer GeneticsMolecular OncologyNeoplasiaCancer CytogeneticsCancer GenomicsCancer Molecular PathologyMalignant NeoplasmsMolecular Classification Of TumorsMolecular Tumor ProfilingBalanced Chromosomal TranslocationDesmoplastic Small Round Cell TumorEwsr1 Gene FusionsFibroblast Growth Factor Receptor AlterationsMolecular Marker ProfilingMolecular Profiling From BiopsySomatic MutationsTumor Mutation Analysis
Abstract Desmoplastic small round cell tumor (DSRCT) is characterized by the EWSR1–WT1 t(11;22) (p13:q12) translocation. Few additional putative drivers have been identified, and research has suffered from a lack of model systems. Next-generation sequencing (NGS) data from 68 matched tumor-normal samples, whole-genome sequencing data from 10 samples, transcriptomic and affymetrix array data, and a bank of DSRCT patient-derived xenograft (PDX) are presented. EWSR1–WT1 fusions were noted to be simple, balanced events. Recurrent mutations were uncommon, but were noted in TERT (3%), ARID1A (6%), HRAS (5%), and TP53 (3%), and recurrent loss of heterozygosity (LOH) at 11p, 11q, and 16q was identified in 18%, 22%, and 34% of samples, respectively. Comparison of tumor-normal matched versus unmatched analysis suggests overcalling of somatic mutations in prior publications of DSRCT NGS data. Alterations in fibroblast growth factor receptor 4 (FGFR4) were identified in 5 of 68 (7%) of tumor samples, whereas differential overexpression of FGFR4 was confirmed orthogonally using 2 platforms. PDX models harbored the pathognomic EWSR1–WT1 fusion and were highly representative of corresponding tumors. Our analyses confirm DSRCT as a genomically quiet cancer defined by the balanced translocation, t(11;22)(p13:q12), characterized by a paucity of secondary mutations but a significant number of copy number alterations. Against this genomically quiet background, recurrent activating alterations of FGFR4 stood out, and suggest that this receptor tyrosine kinase, also noted to be highly expressed in DSRCT, should be further investigated. Future studies of DSRCT biology and preclinical therapeutic strategies should benefit from the PDX models characterized in this study. Implications: These data describe the general quiescence of the desmoplastic small round cell tumor (DSRCT) genome, present the first available bank of DSRCT model systems, and nominate FGFR4 as a key receptor tyrosine kinase in DSRCT, based on high expression, recurrent amplification, and recurrent activating mutations.
61
An integrated map of genetic variation from 1,092 human genomes
The repertoire of mutational signatures in human cancer
Mi Ni Huang, Alvin Wei Tian Ng, Arnoud Boot et al. · Nature · 2020 · 3.7K citations · Full text
Life Sciences, Genetics, Oncology +14
Ahmet Zehir, Ryma Benayed, Ronak Shah et al. · Nature Medicine · 2017 · 3.5K citations
Landscape of somatic mutations in 560 breast cancer whole-genome sequences
Serena Nik‐Zainal, Helen Davies, Johan Staaf et al. · Nature · 2016 · 2.3K citations · Full text
Life Sciences, Genetics, Oncology +14